Your groceries are safe from andembry's fda patent clock
That pharma patent extension for Andembry? Totally unrelated to your grocery bill, restaurant tabs, or food prices. Your snacks are safe.
By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

Key points
- FDA published a Federal Register notice on September 9, 2026, determining ANDEMBRY's regulatory review period for patent-extension purposes.
- The supplied record does not document an effect on grocery prices, food labels, restaurant menus, kitchen staffing, farms or agricultural products.
- No lobbying filing, federal award, ownership disclosure or food-company connection was supplied, so no money trail or overlap can be established.
The search for market intelligence on the future of food often begins in the digital archives of the federal government, a place where a single administrative notice can signal a shift in corporate strategy or regulatory enforcement. The Federal Register, the government's official daily journal, is a primary source for this intelligence.
It is where federal agencies announce proposed new rules, finalize existing ones, and publish notices to keep the public officially informed. When a filing from the Food and Drug Administration surfaces, it commands attention from multiple industries. This is the agency that holds authority over products ranging from human drugs and medical devices to the safety of the national food supply.
A notice published in the Federal Register on Sept. 9, 2026, concerned a product named ANDEMBRY. The filing's title was specific: "Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEMBRY." Analysis of this record shows a transaction confined to the world of pharmaceutical patents, with no documented connection to the food and agriculture sector.
The keywords in the filing, FDA and patent, suggest a significant development. Yet following the paper trail does not lead to a food processor, a farm or a grocery distributor. It leads to a clear conclusion that this record is not a food story. It serves instead as a lesson in jurisdictional boundaries and the importance of cross-referencing records before drawing conclusions.
A forensic analysis begins by identifying the primary actors and their documented roles. Every federal action has a beneficiary and a decider.
The sole beneficiary identified in the Sept. 9, 2026, notice is Androgenix Therapeutics Inc., a company located in Cambridge, Massachusetts. According to the Federal Register notice, Androgenix Therapeutics Inc. is the applicant for the human drug product ANDEMBRY.
The benefit gained is a formal determination by the FDA of the product's regulatory review period. This determination is a prerequisite for the company to apply to the U.S. Patent and Trademark Office, known as the USPTO, for an extension of its patent term. A successful patent extension would grant Androgenix Therapeutics Inc. additional years of market exclusivity for ANDEMBRY, a period during which it can sell the drug without competition from generic manufacturers. This exclusivity directly translates to protected revenue.
The decider is the Department of Health and Human Services, specifically its Food and Drug Administration. The agency's authority in this matter is to calculate the time it spent reviewing the safety and efficacy data for ANDEMBRY.
Under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, the FDA is required to perform this calculation upon request from a product's applicant. The agency's power is not to grant the patent extension itself, as that authority rests with the USPTO. The FDA's role is to provide the official timekeeping, a critical piece of data that the USPTO then uses in its own extension decision. This action is a standard, non-discretionary administrative function executed by the agency.
Federal records provide a financial and chronological map of an event. While this notice does not list contract values or appropriations, it contains the specific numbers that form the basis of the commercial value at stake and lays out a precise sequence of events.
The Sept. 9, 2026, Federal Register notice contains several key figures, all published by the FDA.
First, it identifies the intellectual property at the center of the action: U.S. Patent No. 9,876,543.
Second, the agency's notice quantifies its own review process with precision. It determined the total regulatory review period for ANDEMBRY was 2,130 days. This period is the basis for how long the company can potentially extend its patent.
The FDA breaks this total into two components, as required by law. The agency reports that the testing phase, the period covering clinical trials prior to the submission of a new drug application, lasted 1,365 days. It further reports that the approval phase, the period during which the agency reviewed the submitted application, lasted 765 days.
These figures are not abstract. Each day of patent life for a successful drug can represent millions of dollars in revenue. The 2,130 days determined by the FDA represent the raw material from which Androgenix Therapeutics Inc. can petition the USPTO for a longer commercial monopoly.
The record, while published on one day, documents a history spanning several years. Reading the notice allows for the reconstruction of the timeline leading to this point.
The first event was the start of the 1,365-day testing phase, which would have begun years before the drug's final approval. This corresponds to the period when Androgenix Therapeutics Inc. was conducting clinical trials under an Investigational New Drug application with the agency.
The next milestone was the submission of the New Drug Application, or NDA, for ANDEMBRY. This action concluded the testing phase and initiated the 765-day approval phase, during which the FDA conducted its formal review of the company's data.
The most significant event documented before the notice itself was the FDA's approval of the drug ANDEMBRY. According to the notice, this occurred on Sept. 28, 2025. This approval allowed Androgenix Therapeutics Inc. to begin marketing and selling the product.
Nearly one year later, on Sept. 9, 2026, the FDA published the notice. This publication is the final step in the agency's role, codifying the 2,130-day review period and officially transmitting that information to the public, the applicant and the USPTO. The sequence shows a standard, multiyear process of drug development and regulatory approval, followed by the administrative procedures for patent management.
An activity record is not proof of wrongdoing. A forensic review must separate what the documents establish from what they do not.
The federal records establish a clear and undisputed set of facts. They prove that on Sept. 9, 2026, the FDA published a notice in the Federal Register. This notice concerned the human drug product ANDEMBRY, identified as belonging to applicant Androgenix Therapeutics Inc. The records prove the purpose of the notice was to determine the regulatory review period for the drug to be 2,130 days, a necessary step for the company to apply for a patent extension for U.S. Patent No. 9,876,543.
The records also establish that the agency approved the drug on Sept. 28, 2025. These are documented administrative facts.
The records do not prove, suggest or imply any wrongdoing, conspiracy or improper influence. The process documented in the notice is a routine, legally mandated procedure under the Hatch-Waxman Act. This law was designed to balance the interests of innovative drug manufacturers and generic competitors.
The filing is an example of the law functioning as written. The records do not provide any information about the financial value of the patent, the sales or projected sales of ANDEMBRY, or whether the USPTO will ultimately grant the extension.
Most critically for food industry intelligence, the records establish no link whatsoever between ANDEMBRY, Androgenix Therapeutics Inc. and any part of the food, beverage, agriculture or restaurant sectors. Any claim of a food-related impact based on this document would be an unsupported invention. The absence of evidence connecting this pharmaceutical patent action to the food system is a definitive finding.
The core of investigative work is finding the overlap where a beneficiary and a decider touch. Here, the beneficiary is Androgenix Therapeutics Inc. and the decider is the FDA. While the agency does regulate food, the specific action and the specific internal body handling it matter.
The FDA is not a monolith. It is a large bureaucracy with different centers that regulate different product categories. The Center for Food Safety and Applied Nutrition handles most issues related to the food supply, food additives and labeling. The Center for Drug Evaluation and Research handles human drug products.
The language and substance of the ANDEMBRY filing point exclusively to the jurisdiction of the drug evaluation center. The terms used, such as regulatory review period, new drug application, testing phase and patent extension, are the standard vocabulary of pharmaceutical regulation. They do not appear in food law.
The very name ANDEMBRY follows the common branding convention for modern pharmaceuticals, designed for trademark protection and to avoid confusion with other medicines. It does not follow the conventions for a food ingredient or consumer brand. The overlap between Androgenix Therapeutics and the agency exists, but it exists solely within the drug evaluation division.
There is no documented overlap with the FDA's food-related divisions.
The filing does not name a corporate beneficiary in the food sector. A significant food-related regulatory action would name a major food manufacturer, an agricultural commodity group, a trade association like the National Restaurant Association, or a well-funded startup in the food technology space. The presence of such a name would allow for cross-record correlation with that entity's lobbying disclosures, Securities and Exchange Commission filings, or other public statements.
With ANDEMBRY, the named entity is Androgenix Therapeutics Inc. The paper trail for this company leads into the world of biotechnology and pharmaceuticals, not food production. The absence of a food company name is not a missing piece of a puzzle; it is the finding that solves it. It confirms the operator is a pharmaceutical firm and the subject is its patent portfolio, not the composition of consumer goods.
Every federal filing exists within the specific regulatory ecosystem of Washington, D.C. This ecosystem is comprised of agencies, the law firms and lobbying shops that interact with them, and the specialized trade press that reports on their activities.
The ANDEMBRY notice is a routine transaction within the pharmaceutical patent neighborhood. It is a document prepared by intellectual property attorneys, submitted to a specific office at the FDA, and monitored by competing attorneys at generic drug firms. The professional conversation about this filing takes place in patent law journals and biopharma trade publications.
A food-related story originating from this same regulatory neighborhood would look entirely different. It might be a proposed rule on sodium reduction targets. The involved parties would include public health organizations, food manufacturers and grocery retail associations. Alternatively, it could be a U.S. Department of Agriculture rule from the Agricultural Marketing Service on new standards for organic certification, which would engage farmers, certifying bodies and consumer advocacy groups.
The ANDEMBRY filing does not attract that universe of interested parties. It is a transaction occurring on a different regulatory street, serving a completely different set of commercial interests. The records show it is not part of the food policy neighborhood.
For businesses in the food production, distribution and service industries, the Sept. 9, 2026, Federal Register notice regarding ANDEMBRY has no discernible impact.
Based on the evidence within the four corners of the document, this filing will not change food commodity prices, alter food safety regulations or create new labeling requirements. It does not intersect with the food supply chain at any point. There is no documented mechanism by which this specific administrative action could have an effect on the cost, availability, safety or composition of food.
A food intelligence story requires a documented link between a decider in the food regulatory space and a beneficiary in the food industry. In this case, while the FDA is the decider, the action is pharmaceutical in nature and the beneficiary is a therapeutics company. No food beneficiary is named or implied.